共 153 条
[1]
Capitain O(2008)The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer Pharmacogenom J 8 256-267
[2]
Boisdron-Celle M(2007)Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study J Cancer Res Clin Oncol 134 75-82
[3]
Poirier A-L(2000)Dose and time dependencies of 5-fluorouracil pharmacokinetics Clin Pharmacol Ther 68 270-279
[4]
Kosmas C(2016)Therapeutic drug monitoring of 5-fluorouracil Cancer Chemother Pharmacol 78 447-464
[5]
Kallistratos MS(1991)Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance Oncology 48 277-281
[6]
Kopterides P(2013)Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study Cancer Chemother Pharmacol 71 361-370
[7]
Terret C(1998)Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis Eur J Cancer 34 92-97
[8]
Erdociain E(2013)5-fluorouracile: MSI, pharmacocinétique, DPD, TYMS et MTHFR Médecine Personnal en cancérologie Dig 16 215-237
[9]
Guimbaud R(1989)Clinical Pharmacology of 5-Fluorouracil Clin Pharmacokinet 40 939-950
[10]
Lee JJ(2004)Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil Eur J Cancer 14 13-18